Czech Republic Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Czech Republic Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Czech Republic Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: A strong economic outlook will drive continued growth in both the pharmaceuticals and healthcare markets over the coming years. As a result of the advanced nature of the market, verging on a par with Western European markets, the Czech Republic will remain the one of the most attractive markets in Central and Eastern Europe for multinational drugmakers.

Headline Expenditure Projections

  • Pharmaceuticals: CZK78.83bn (USD3.02bn) in 2015 to CZK81.15bn (USD3.28bn) in 2016; +3.0% in local currency terms and +8.8 % in US dollar terms. Forecasts unchanged from last quarter.

  • Healthcare: CZK312.52bn (USD11.97bn) in 2015 to CZK325.75bn (USD13.19bn) in 2016; +4.2% in local currency terms and +10.2% in US dollar terms. Forecasts unchanged from last quarter .

Headline Pharmaceuticals & Healthcare Forecasts (Czech Republic 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: State Institute for Drug Control (SUKL), World Health Organisation, BMI
Pharmaceutical sales, USDbn 3.490 3.020 3.280 3.670 4.040 4.150 4.310
Pharmaceutical sales, % of GDP 1.80 1.76 1.78 1.77 1.75 1.72 1.70
Pharmaceutical sales, % of health expenditure 25.5 25.2 24.9 24.6 24.3 24.0 23.7
Health spending, USDbn 13.660 11.970 13.190 14.890 16.600 17.280 18.190

Risk/Reward Index

In Q4 2016, the Czech Republic's BMI Risk/Reward Index (RRI) score has been upgraded slightly from the previous quarter to 65.5 out of 100. Within our RRI matrix, the Czech Republic is ranked as the most attractive market in the Central and Eastern European (CEE) region to innovative drugmakers. The Czech pharmaceutical market score is driven by high pharmaceutical expenditure per capita, an ageing population and a favourable urban-rural distribution, but dragged down by a challenging pricing and reimbursement environment.

Latest Updates

  • In July 2016, the Ministry of Health outlined its intentions to reduce the upper limit for drug spending by pensioners, from CZK2,000 (USD81.6) to CZK1,000 (USD40.8).

  • On June 6 2016, representatives from the Czech and Slovak Ministries of Health met to discuss cooperation with regard to the countries' drug policies.

  • On May 30 2016, the government had approved an increase to state healthcare insurance funding by CZK3.6bn (USD148mn) for 2017.

BMI Economic View

Czech economic growth will slow considerably in 2016 on the back of sharply declining fixed investment inflows from EU funds. Economic fundamentals remain strong, however, as household consumption and strong manufacturing output will be the key drivers of economic activity.

BMI Political View

With upcoming elections in 2016 and 2017, we expect the ruling Social Democrats to increasingly adopt eurosceptic and populist policies. In combination with surging support for anti-establishment parties, this will align the Czech Republic closer with its central European peers.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Czech Republic 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Czech Republic 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
27
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Czech Republic 2014-2020)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Czech Republic 2014-2020)
30
Industry Risk Reward Index
31
Central And Eastern Europe Risk/Reward Index - Q4 2016
31
Czech Republic - Risk/Reward Index
38
Rewards
38
Risks
39
Regulatory Review
40
Intellectual Property Issues
40
Pricing Regime
41
Reimbursement Regime
42
Market Overview
47
Healthcare Sector
48
Table: Healthcare Resources (Czech Republic 2010-2015)
50
Table: Healthcare Personnel (Czech Republic 2010-2015)
50
Table: Healthcare Activity (Czech Republic 2010-2015)
51
Research & Development
54
Clinical Trials
54
Epidemiology
56
Competitive Landscape
59
Research-Based Industry
59
Table: Multinational Market Activity
59
Generic Drugmakers
60
Pharmaceutical Distribution
61
Pharmaceutical Retail Sector
61
Company Profile
63
Zentiva (Sanofi)
63
Demographic Data
67
Demographic Forecast
67
Table: Population Headline Indicators (Czech Republic 1990-2025)
68
Table: Key Population Ratios (Czech Republic 1990-2025)
68
Table: Urban/Rural Population & Life Expectancy (Czech Republic 1990-2025)
69
Table: Population By Age Group (Czech Republic 1990-2025)
69
Table: Population By Age Group % (Czech Republic 1990-2025)
70
Glossary
72
Methodology
74
Pharmaceutical Expenditure Forecast Model
74
Healthcare Expenditure Forecast Model
74
Notes On Methodology
75
Risk/Reward Index Methodology
76
Index Overview
77
Table: Pharmaceutical Risk/Reward Index Indicators
77
Indicator Weightings
78

The Czech Republic Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech Republic pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Czech Republic, to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Czech Republic.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.